- Home
- SANG vs FATE Comparison
SANG vs FATE Comparison
Compare SANG & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANG
- FATE
- Stock Information
- Founded
- SANG 1984
- FATE 2007
- Country
- SANG Canada
- FATE United States
- Employees
- SANG N/A
- FATE N/A
- Industry
- SANG Computer Software: Programming Data Processing
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SANG Technology
- FATE Health Care
- Exchange
- SANG Nasdaq
- FATE Nasdaq
- Market Cap
- SANG 189.6M
- FATE 177.7M
- IPO Year
- SANG 2021
- FATE 2013
- Fundamental
- Price
- SANG $5.74
- FATE $1.16
- Analyst Decision
- SANG
- FATE Hold
- Analyst Count
- SANG 0
- FATE 7
- Target Price
- SANG N/A
- FATE $3.83
- AVG Volume (30 Days)
- SANG 4.8K
- FATE 2.0M
- Earning Date
- SANG 05-08-2025
- FATE 08-12-2025
- Dividend Yield
- SANG N/A
- FATE N/A
- EPS Growth
- SANG N/A
- FATE N/A
- EPS
- SANG N/A
- FATE N/A
- Revenue
- SANG $238,264,000.00
- FATE $13,335,000.00
- Revenue This Year
- SANG N/A
- FATE N/A
- Revenue Next Year
- SANG $2.91
- FATE N/A
- P/E Ratio
- SANG N/A
- FATE N/A
- Revenue Growth
- SANG N/A
- FATE 105.85
- 52 Week Low
- SANG $4.08
- FATE $0.66
- 52 Week High
- SANG $7.99
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- SANG 52.55
- FATE 44.54
- Support Level
- SANG $5.55
- FATE $1.11
- Resistance Level
- SANG $5.96
- FATE $1.23
- Average True Range (ATR)
- SANG 0.14
- FATE 0.15
- MACD
- SANG -0.02
- FATE -0.04
- Stochastic Oscillator
- SANG 56.00
- FATE 7.04
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.